Research progress on the premature ovarian failure caused by cisplatin therapy

Zelin Li; Haodong Qi; Zhengyang Li; Yuxuan Bao; Kangping Yang; Qinghua Min

doi:10.3389/fonc.2023.1276310

Research progress on the premature ovarian failure caused by cisplatin therapy

Front Oncol. 2023 Nov 20:13:1276310. doi: 10.3389/fonc.2023.1276310. eCollection 2023.

Authors

Zelin Li^#¹, Haodong Qi^#¹, Zhengyang Li^#¹, Yuxuan Bao², Kangping Yang³, Qinghua Min⁴

Affiliations

¹ The First Clinical Medical College of Nanchang University, Nanchang, China.
² Queen Mary School of Nanchang University, Nanchang, China.
³ The Second Clinical Medical College of Nanchang University, Nanchang, China.
⁴ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

^# Contributed equally.

Abstract

Cisplatin is a common anticancer drug able to kill tumor cells, but it causes adverse reactions in the kidney, digestive tract, and other systems. The antitumor effects of cisplatin are mainly due to its ability to bind to the DNA in tumor cells to prevent replication, thereby reducing RNA and protein syntheses, leading to cell damage and death. Cisplatin has a wide range of applications; it can be used to treat cervical, thyroid, ovarian, and other cancers. Cisplatin has a beneficial therapeutic effect, but its therapeutic selectivity is poor. In addition to eliminating diseased target cells, cisplatin can damage normal cells; in women of reproductive age being treated for cancer, cisplatin can lead to ovarian function impairment, premature ovarian failure (POF), and/or infertility. Therefore, reducing the adverse effects of cisplatin on ovarian function is an important topic in clinical research. In this paper, we explore the research progress on the POF caused by cisplatin treatment.

Keywords: apoptosis; cisplatin; premature ovarian failure; protection strategies; research and analysis.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Jiangxi Provincial Chemotherapy Toxicity Research Fund (NO.20220605A).